Citi analyst Patrick Donnelly downgraded Illumina (ILMN) to Neutral from Buy with a price target of $165, down from $190. The firm sees less clarity on the conpany’s growth ramp given more pronounced pricing headwinds in the first half of 2025 from the NovaSeq X ramp and believes the cost out story is appropriately priced into the multiple.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina enters licensing agreement with Lonza
- Illumina releasing expanded version of TruSight Oncology portfolio
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls
- Illumina resumed with an Equal Weight at Morgan Stanley